Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Bnb Plus's Business Segments
Bnb Plus's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
2
Largest Segment
Therapeutic DNA Production
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Therapeutic DNA Production62.3%
- DNA Tagging and Security Products37.7%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Therapeutic DNA Production | $ 1 | 62.3% |
| DNA Tagging and Security Products | $ 0 | 37.7% |
Revenue by Product & Service Category - Q2 FY2026
- Product98.4%
- Large Scale DNA Production95%
- Supply chain4.7%
- Service1.6%
- Research and Development Services0.2%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 1 | 98.4% |
| Large Scale DNA Production | $ 1 | 95% |
| Supply chain | $ 0 | 4.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Bnb Plus
The company operates as a digital asset treasury (DAT) firm, focusing on accumulating and utilizing BNB, the native cryptocurrency of the Binance blockchain ecosystem, as its primary reserve asset. It uses proceeds from financings and potential cash flow to accumulate BNB and generate yield through Binance native and decentralized finance (DeFi) opportunities, including staking, restaking, liquid staking, participation in the Binance Launch Pool, liquidity provision, and collateralization strategies. Through its subsidiary, LineaRx, Inc., the company commercializes proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets, enabling cell-free manufacturing of DNA and RNA for advanced biotherapeutics and diagnostics. The company also holds units of OBNB Osprey BNB Chain Trust and plans to sell these units or redeem underlying BNB assets to support its BNB strategy. The BNB ecosystem supports various DeFi applications, NFTs, gaming, payments, staking, and governance, operating on a Proof of Staked Authority consensus mechanism with low transaction fees and high throughput. The company acknowledges regulatory and market risks associated with BNB, including scrutiny of burn mechanisms and potential price manipulation concerns related to Binance and its founder, who hold significant BNB positions.
The company operates primarily in the Therapeutic DNA Production Services segment and previously in the DNA Tagging Security Products segment. The Therapeutic DNA Production Services segment utilizes proprietary technologies and know-how protected by patents, trade secrets, and trademarks. As of December 15, 2025, the company's patent portfolio for this segment includes eight issued patents and eight pending patent applications in the United States, as well as twelve issued foreign patents and eight pending foreign patent applications. The company operates in a competitive market with various competitors. Customers in these segments are generally not obligated to make purchases and may terminate orders or contracts with minimal or no financial penalty, which presents risks to the company's revenue and business results.